Literature DB >> 436200

Immediate effects of hydralazine-isosorbide dinitrate combination on exercise capacity and exercise hemodynamics in patients with left ventricular failure.

J A Franciosa, J N Cohn.   

Abstract

Resting hemodynamics improve during vasodilator administration in patients, with congestive heart failure (CHF), but the effects of these agents on exercise is unknown. Twenty-two patients with class II or III CHF performed bicycle exercise to symptomatic maximum before and 90 minutes after random double-blind administration of oral hydralazine (100 mg) and isosorbide dinitrate (40 mg) (11 patients, group 1) or placebo (11 patients, group 2). Exercise duration was unchanged after treatment in either group. Maximal oxygen consumption changed insignificantly in both groups, from 12.6 +/- 1.2 (SEM) to 13.6 +/- 1.6 ml/kg/min in group 1, and from 11.7 +/- 1.4 to 13.4 +/- 1.7 ml/kg/min in group 2. Maximal cardiac index was unchanged in both group 1 (4.00 +/- 0.33 to 4.41 +/- 0.29 l/min/m2) and group 2 (4.11 +/- 0.43 to 4.14 +/- 0.42 l/min/m2). Systemic vascular resistance at peak exercise was also unchanged in both group 1 (14.1 +/- 1.6 to 11.8 +/- 1.0 units) and group 2 (14.7 +/- 1.6 to 13.5 +/- 1.6 units). at submaximal exercise (300 kilopond-meters/min), however, cardiac index after treatment increased in group 1 (0.51 +/- 0.18 l/min/m2, p less than 0.05) and systemic vascular resistance decreased (-3.3 +/- 1.3 units, p less than 0.05), but were unchanged in group 2. Thus, although vasodilators do not improve maximal exercise capacity acutely, they can improve hemodynamics at lower work loads which may, therefore, be better tolerated in patients with CHF.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 436200     DOI: 10.1161/01.cir.59.6.1085

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  10 in total

Review 1.  Vasodilators in heart failure. Conclusions from V-HeFT II and rationale for V-HeFT III.

Authors:  J N Cohn
Journal:  Drugs       Date:  1994       Impact factor: 9.546

Review 2.  Drug treatment of heart failure.

Authors:  C T Dollery; L Corr
Journal:  Br Heart J       Date:  1985-09

3.  Vasodilator treatment with isosorbide dinitrate and hydralazine in chronic heart failure.

Authors:  B M Massie; B Kramer; E Shen; F Haughom
Journal:  Br Heart J       Date:  1981-04

4.  Effect of vasodilator drugs on exercise performance in cardiac failure. Comparison of hydralazine and prazosin.

Authors:  D H Fitchett; M Pathé; R Pardy; P Despas
Journal:  Br Heart J       Date:  1980-08

Review 5.  The treatment of heart failure. A methodological review of the literature.

Authors:  G H Guyatt
Journal:  Drugs       Date:  1986-12       Impact factor: 9.546

6.  Effects of vasodilator treatment with felodipine on haemodynamic responses to treadmill exercise in congestive heart failure.

Authors:  A D Timmis; P Smyth; J F Kenny; S Campbell; D E Jewitt
Journal:  Br Heart J       Date:  1984-09

7.  Vasodilatation with captopril and prazosin in chronic heart failure: double blind study at rest and on exercise.

Authors:  J Bayliss; R Canepa-Anson; M S Norell; P Poole-Wilson; G Sutton
Journal:  Br Heart J       Date:  1986-03

Review 8.  Vasodilator therapy in chronic congestive heart failure.

Authors:  A B Schwartz; K Chatterjee
Journal:  Drugs       Date:  1983-08       Impact factor: 9.546

Review 9.  Glyceryl trinitrate (nitroglycerin) ointment and isosorbide dinitrate: a review of their pharmacological properties and therapeutic use.

Authors:  U Elkayam; W S Aronow
Journal:  Drugs       Date:  1982-03       Impact factor: 9.546

Review 10.  Vasodilator therapy without converting-enzyme inhibition in congestive heart failure--usefulness and limitations.

Authors:  W J Remme
Journal:  Cardiovasc Drugs Ther       Date:  1989-06       Impact factor: 3.727

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.